Intratumorally anchored cytokine therapy

References

• Garber K. Immune agonist antibodies face critical test. Nat Rev Drug Discov. 2020;19(1):3–5. PubMed PMID: 31907434.
   PubMedGoogle Scholar
• Holder PG, Lim SA, Huang CS, et al. Engineering interferons and interleukins for cancer immunotherapy. Adv Drug Deliv Rev. 2022;182:114112. Epub 20220124. PubMed PMID: 35085624.
   PubMedGoogle Scholar
• Mansurov A, Lauterbach A, Budina E, et al.Immunoengineering approaches for cytokine therapy.Am J Physiol Cell Physiol.2021;321(2):C369–C83; Epub 20210707. PubMed PMID: 34232748;
   PubMedGoogle Scholar
• Nirschl CJ, Brodkin HR, Hicklin DJ, et al. Discovery of a conditionally activated interleukin-2 that promotes anti-tumor immunity and induces tumor regression. Cancer Immunol Res. 2022;10:581–596. Epub 20220314. PubMed PMID: 35286392.
   PubMedGoogle Scholar
• Hsu EJ, Cao X, Moon B, et al. A cytokine receptor-masked IL2 prodrug selectively activates tumor-infiltrating lymphocytes for potent antitumor therapy. Nat Commun. 2021;12(1):2768. Epub 20210513. PubMed PMID: 33986267; PubMed Central PMCID: PMC8119481
   PubMedGoogle Scholar
• Erster O, Thomas JM, Hamzah J, et al. Site-specific targeting of antibody activity in vivo mediated by disease-associated proteases. J Control Release. 2012;161(3):804–812. : Epub 20120523. PubMed PMID: 22634092; PubMed Central PMCID: PMC3412904
   PubMed Web of Science ®Google Scholar
• Adams G, Vessillier S, Dreja H, et al.Targeting cytokines to inflammation sites.Nat Biotechnol.2003;21(11):1314–1320; Epub 20031005. PubMed PMID: 14528315;
   PubMedGoogle Scholar
• Mansurov A, Hosseinchi P, Chang K, et al. Masking the immunotoxicity of interleukin-12 by fusing it with a domain of its receptor via a tumour-protease-cleavable linker. Nat Biomed Eng. 2022. Epub 20220509. https://doi.org/10.1038/s41551-022-00888-0. PubMed PMID: 35534574.
   Google Scholar
• Xu Y, Carrascosa LC, Yeung YA, et al. An engineered IL15 cytokine mutein fused to an Anti-PD1 improves intratumoral T-cell function and antitumor immunity. Cancer Immunol Res. 2021;9(10):16–25. Epub 20210810. PubMed PMID: 34376502
   Google Scholar
• Pogue SL, Taura T, Bi M, et al. Targeting attenuated interferon-α to myeloma cells with a CD38 antibody induces potent tumor regression with reduced off-target activity. PLoS One. 2016;11(9):e0162472. Epub 20160909. PubMed PMID: 27611189; PubMed Central PMCID: PMC5017640
   PubMedGoogle Scholar
• Spangler JB, Moraga I, Mendoza JL, et al. Insights into cytokine-receptor interactions from cytokine engineering. Annu Rev Immunol. 2015;33:139–167. Epub 20141210. PubMed PMID: 25493332; PubMed Central PMCID: PMC4445396.
   PubMed Web of Science ®Google Scholar
• Glassman CR, Mathiharan YK, Jude KM, et al. Structural basis for IL-12 and IL-23 receptor sharing reveals a gateway for shaping actions on T versus NK cells. Cell. 2021;184(4):983–99.e24. PubMed PMID: 33606986; PubMed Central PMCID: PMC7899134.
   PubMed Web of Science ®Google Scholar
• Chiocca EA, Yu JS, Lukas RV, et al. Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: results of a phase 1 trial. Sci Transl Med. 2019;11(505). PubMed PMID: 31413142; PubMed Central PMCID: PMC7286430. https://doi.org/10.1126/scitranslmed.aaw5680.
   Google Scholar
• Kaufman HL, Shalhout SZ, Iodice G. Talimogene Laherparepvec: moving From First-In-Class to Best-In-Class. Front Mol Biosci. 2022;9:834841. Epub 20220222. PubMed PMID: 35274007; PubMed Central PMCID: PMC8901478.
   PubMedGoogle Scholar
• Li Y, Su Z, Zhao W, et al. Multifunctional oncolytic nanoparticles deliver self-replicating IL-12 RNA to eliminate established tumors and prime systemic immunity. Nat Cancer. 2020;1(9):882–893. Epub 20200810. PubMed PMID: 34447945; PubMed Central PMCID: PMC8386348
   PubMedGoogle Scholar
• Hewitt SL, Bailey D, Zielinski J, et al. Intratumoral IL12 mRNA therapy promotes TH1 transformation of the tumor microenvironment. Clin Cancer Res. 2020;26(23):6284–6298. Epub 20200817. PubMed PMID: 32817076
   PubMed Web of Science ®Google Scholar
• Hotz C, Wagenaar TR, Gieseke F, et al. Local delivery of mRNA-encoded cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models. Sci Transl Med. 2021;13(610):eabc7804. Epub 20210908. PubMed PMID: 34516826
   PubMed Web of Science ®Google Scholar
• Nash AM, Jarvis MI, Aghlara-Fotovat S, et al. Clinically translatable cytokine delivery platform for eradication of intraperitoneal tumors. Sci Adv. 2022;8(9):eabm1032. Epub 20220302. PubMed PMID: 35235346; PubMed Central PMCID: PMC8890714
   PubMedGoogle Scholar
• Daud AI, DeConti RC, Andrews S, et al. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol. 2008;26(36):5896–5903. Epub 20081124. PubMed PMID: 19029422; PubMed Central PMCID: PMC2645111
   PubMed Web of Science ®Google Scholar
• Park CG, Hartl CA, Schmid D, et al. Extended release of perioperative immunotherapy prevents tumor recurrence and eliminates metastases. Sci Transl Med. 2018;10(433): PubMed PMID: 29563317. https://doi.org/10.1126/scitranslmed.aar1916.
   Web of Science ®Google Scholar
• Zaharoff DA, Hance KW, Rogers CJ, et al. Intratumoral immunotherapy of established solid tumors with chitosan/IL-12. J Immunother. 2010;33(7):697–705. PubMed PMID: 20664357; PubMed Central PMCID: PMC3468951.
   PubMed Web of Science ®Google Scholar
• Marabelle A, Kohrt H, Caux C, et al. Intratumoral immunization: a new paradigm for cancer therapy. Clin Cancer Res. 2014;20(7):1747–1756. PubMed PMID: 24691639; PubMed Central PMCID: PMC3979477.
   PubMed Web of Science ®Google Scholar
• Huang A, Pressnall MM, Lu R, et al. Human intratumoral therapy: linking drug properties and tumor transport of drugs in clinical trials. J Control Release. 2020;326:203–221. Epub 20200714. PubMed PMID: 32673633.
   PubMed Web of Science ®Google Scholar
• Marabelle A, Andtbacka R, Harrington K, et al. Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT). Ann Oncol. 2018;29(11):2163–2174. PubMed PMID: 30295695; PubMed Central PMCID: PMC6290929.
   PubMed Web of Science ®Google Scholar
• Tselikas L, Champiat S, Sheth RA, et al. Interventional radiology for local immunotherapy in oncology. Clin Cancer Res. 2021;27(10):2698–2705. Epub 20210108. PubMed PMID: 33419781
   PubMedGoogle Scholar
• Muñoz NM, Williams M, Dixon K, et al. Influence of injection technique, drug formulation and tumor microenvironment on intratumoral immunotherapy delivery and efficacy. J Immunother Cancer. 2021;9(2):e001800. PubMed PMID: 33589526; PubMed Central PMCID: PMC7887346.
   PubMed Web of Science ®Google Scholar
• Hammerich L, Marron TU, Upadhyay R, et al. Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination. Nat Med. 2019;25(5):814–824. Epub 20190408. PubMed PMID: 30962585
   PubMed Web of Science ®Google Scholar
• Weide B, Neri D, Elia G. Intralesional treatment of metastatic melanoma: a review of therapeutic options. Cancer Immunol Immunother.2017;66(5):647–656; Epub 20170111. PubMed PMID: 28078357; PubMed Central PMCID: PMC6126622;
   PubMed Web of Science ®Google Scholar
• Milhem M, Zakharia Y, Davar D, et al. Durable responses in anti-PD-1 refractory melanoma following intratumoral injection of Toll-like receptor 9 (TLR9) agonist CMP-001, in combination with pembrolizumab. J Immunother Cancer. 2020. https://doi.org/10.1136/LBA2019.4.
   Google Scholar
• Kent AJ, Byrnes KA, Chang SH. State of the art: robotic bronchoscopy. Semin Thorac Cardiovasc Surg.2020;32(4):1030–1035; Epub 20200823. PubMed PMID: 32846232;
   PubMedGoogle Scholar
• Rohner NA, Thomas SN. Melanoma growth effects on molecular clearance from tumors and biodistribution into systemic tissues versus draining lymph nodes. J Control Release. 2016;223:99–108. Epub 20151223. PubMed PMID: 26721446; PubMed Central PMCID: PMC4724472.
   PubMedGoogle Scholar
• Kwong B, Liu H, Irvine DJ. Induction of potent anti-tumor responses while eliminating systemic side effects via liposome-anchored combinatorial immunotherapy. Biomaterials.2011;32(22):5134–5147; Epub 20110422. PubMed PMID: 21514665; PubMed Central PMCID: PMC3140866;
   PubMed Web of Science ®Google Scholar
• Kwong B, Gai SA, Elkhader J, et al.Localized immunotherapy via liposome-anchored Anti-CD137 + IL-2 prevents lethal toxicity and elicits local and systemic antitumor immunity.Cancer Res.2013;73(5):1547–1558; Epub 20130222. PubMed PMID: 23436794; PubMed Central PMCID: PMC3594475;
   PubMed Web of Science ®Google Scholar
• Hanes J, Sills A, Zhao Z, et al. Controlled local delivery of interleukin-2 by biodegradable polymers protects animals from experimental brain tumors and liver tumors. Pharm Res. 2001;18(7):899–906. PubMed PMID: 11496947.
   PubMed Web of Science ®Google Scholar
• van Herpen CM, Looman M, Zonneveld M, et al. Intratumoral administration of recombinant human interleukin 12 in head and neck squamous cell carcinoma patients elicits a T-helper 1 profile in the locoregional lymph nodes. Clin Cancer Res. 2004;10(8):2626–2635. PubMed PMID: 15102664.
   PubMed Web of Science ®Google Scholar
• Neri D, Carnemolla B, Nissim A, et al. Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform. Nat Biotechnol. 1997;15(12):1271–1275. PubMed PMID: 9359110.
   PubMed Web of Science ®Google Scholar
• Sauer S, Erba PA, Petrini M, et al. Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients. Blood. 2009;113(10):2265–2274. Epub 20090108. PubMed PMID: 19131554
   PubMed Web of Science ®Google Scholar
• Jailkhani N, Ingram JR, Rashidian M, et al. Noninvasive imaging of tumor progression, metastasis, and fibrosis using a nanobody targeting the extracellular matrix. Proc Natl Acad Sci U S A. 2019;116(28):14181–14190. Epub 20190508. PubMed PMID: 31068469; PubMed Central PMCID: PMC6628802
   PubMed Web of Science ®Google Scholar
• Tzeng A, Kwan BH, Opel CF, et al.Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution.Proc Natl Acad Sci U S A.2015;112(11):3320–3325; Epub 2015/03/02. PubMed PMID: 25733854; PubMed Central PMCID: PMC4371941;
   PubMedGoogle Scholar
• Danielli R, Patuzzo R, Di Giacomo AM, et al. Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study. Cancer Immunol Immunother. 2015;64(8):999–1009. Epub 20150514. PubMed PMID: 25971540
   PubMed Web of Science ®Google Scholar
• Lutz E, Jailkhani N, Momin N, et al. Nanobody-IL-2 fusions targeting the tumor microenvironment suppress solid tumor growth in mice. Submitted. 2022.
   Google Scholar
• Pretto F, Elia G, Castioni N, et al.Preclinical evaluation of IL2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy.Cancer Immunol Immunother.2014;63(9):901–910; Epub 20140604. PubMed PMID: 24893857;
   PubMed Web of Science ®Google Scholar
• Pasche N, Wulhfard S, Pretto F, et al.The antibody-based delivery of interleukin-12 to the tumor neovasculature eradicates murine models of cancer in combination with paclitaxel.Clin Cancer Res.2012;18(15):4092–4103; Epub 20120612. PubMed PMID: 22693354;
   PubMedGoogle Scholar
• Riegler J, Labyed Y, Rosenzweig S, et al. Tumor elastography and its association with collagen and the tumor microenvironment. Clin Cancer Res. 2018;24(18):4455–4467. Epub 20180524. PubMed PMID: 29798909
   PubMedGoogle Scholar
• Ishihara J, Ishihara A, Sasaki K, et al. Targeted antibody and cytokine cancer immunotherapies through collagen affinity. Sci Transl Med. 2019;11(487). PubMed PMID: 30971453; PubMed Central PMCID: PMC6541444. https://doi.org/10.1126/scitranslmed.aau3259.
   Google Scholar
• Momin N, Mehta NK, Bennett NR, et al. Anchoring of intratumorally administered cytokines to collagen safely potentiates systemic cancer immunotherapy. Sci Transl Med. 2019;11(498). https://doi.org/10.1126/scitranslmed.aaw2614. PubMed PMID: 31243150; PubMed Central PMCID: PMC7811803
   PubMed Web of Science ®Google Scholar
• Schmidt MM, Wittrup KD. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther. 2009;8(10):2861–2871. PubMed PMID: 19825804; PubMed Central PMCID: PMC4078872.
   PubMed Web of Science ®Google Scholar
• Momin N, Palmeri JR, Lutz EA, et al. Maximizing response to intratumoral immunotherapy in mice by tuning local retention. Nat Commun. 2022;13(1):109. Epub 20220110. PubMed PMID: 35013154; PubMed Central PMCID: PMC8748612
   PubMedGoogle Scholar
• Hutmacher C, Neri D. Antibody-cytokine fusion proteins: biopharmaceuticals with immunomodulatory properties for cancer therapy. Adv Drug Deliv Rev. 2019;141:67–91. Epub 20180907. PubMed PMID: 30201522.
   PubMedGoogle Scholar
• Ribba B, Boetsch C, Nayak T, et al. Prediction of the optimal dosing regimen using a mathematical model of tumor uptake for immunocytokine-based cancer immunotherapy. Clin Cancer Res. 2018;24(14):3325–3333. Epub 20180220. PubMed PMID: 29463551
   PubMed Web of Science ®Google Scholar
• van Brummelen EMJ, Huisman MC, de Wit-van der Veen LJ, et al. Zr-labeled CEA-targeted IL-2 variant immunocytokine in patients with solid tumors: CEA-mediated tumor accumulation and role of IL-2 receptor-binding. Oncotarget. 2018;9(37):24737–24749. Epub 20180515. PubMed PMID: 29872502; PubMed Central PMCID: PMC5973872
   PubMedGoogle Scholar
• Baniel CC, Sumiec EG, Hank JA, et al.Intratumoral injection reduces toxicity and antibody-mediated neutralization of immunocytokine in a mouse melanoma model. J Immunother Cancer. 2020;8(2):e001262. PubMed PMID: 33115944; PubMed Central PMCID: PMC7594540
   PubMedGoogle Scholar
• Hong Y, Robbins Y, Yang X, et al. Cure of syngeneic carcinomas with targeted IL-12 through obligate reprogramming of lymphoid and myeloid immunity. JCI Insight. Epub 20220308. https://doi.org/10.1172/jci.insight.157448. Epub 20220308. 2022; 7: 5
   Google Scholar
• Zhang Y, Li N, Suh H, et al.Nanoparticle anchoring targets immune agonists to tumors enabling anti-cancer immunity without systemic toxicity.Nat Commun.2018;9(1):6; Epub 20180102. PubMed PMID: 29295974; PubMed Central PMCID: PMC5750237;
   PubMedGoogle Scholar
• Lewis ND, Sia CL, Kirwin K, et al. Exosome surface display of il12 results in tumor-retained pharmacology with superior potency and limited systemic exposure compared with recombinant IL12. Mol Cancer Ther. 2021;20(3):523–534. Epub 20201221. PubMed PMID: 33443094
   PubMed Web of Science ®Google Scholar
• Moyer TJ, Kato Y, Abraham W, et al. Engineered immunogen binding to alum adjuvant enhances humoral immunity. Nat Med. 2020;26(3):430–440. Epub 20200217. PubMed PMID: 32066977; PubMed Central PMCID: PMC7069805
   PubMed Web of Science ®Google Scholar
• Agarwal Y, Milling LE, Chang JYH, et al. Intratumourally injected alum-tethered cytokines elicit potent and safer local and systemic anticancer immunity. Nat Biomed Eng. Epub 20220110. Epub 20220110. 2022;6:129–143.
   PubMedGoogle Scholar
• Kwan BH, Zhu EF, Tzeng A, et al. Integrin-targeted cancer immunotherapy elicits protective adaptive immune responses. J Exp Med. 2017;214(6):1679–1690. Epub 20170504. PubMed PMID: 28473400; PubMed Central PMCID: PMC5460993
   PubMedGoogle Scholar
• Moynihan KD, Opel CF, Szeto GL, et al. Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses. Nat Med. 2016;22(12):1402–1410. Epub 20161024. PubMed PMID: 27775706; PubMed Central PMCID: PMC5209798
   PubMed Web of Science ®Google Scholar
• Rothschilds A, Tzeng A, Mehta NK, et al.Order of administration of combination cytokine therapies can decouple toxicity from efficacy in syngeneic mouse tumor models.Oncoimmunology.2019;8(5):e1558678; Epub 2019/02/19. PubMed PMID: 31069130; PubMed Central PMCID: PMC6492973;
   PubMed Web of Science ®Google Scholar
• Tzeng A, Kauke MJ, Zhu EF, et al. Temporally programmed CD8α. Cell Rep. 2016;17(10):2503–2511. PubMed PMID: 27926855; PubMed Central PMCID: PMC5204262.
   PubMedGoogle Scholar
• Wittrup KD. Antitumor antibodies can drive therapeutic T cell responses. Trends Cancer.2017;3(9):615–620; Epub 20170729. PubMed PMID: 28867165; PubMed Central PMCID: PMC5657573;
   PubMedGoogle Scholar
• Zhu EF, Gai SA, Opel CF, et al. Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2. Cancer Cell. 2015;27(4):489–501. PubMed PMID: 25873172; PubMed Central PMCID: PMC4398916.
   PubMedGoogle Scholar
• Abuodeh Y, Venkat P, Kim S. Systematic review of case reports on the abscopal effect. Curr Probl Cancer.2016;40(1):25–37; Epub 20151009. PubMed PMID: 26582738;
   PubMed Web of Science ®Google Scholar
• Formenti SC, Rudqvist NP, Golden E, et al. Radiotherapy induces responses of lung cancer to CTLA-4 blockade. Nat Med. 2018;24(12):1845–1851. Epub 20181105. PubMed PMID: 30397353; PubMed Central PMCID: PMC6286242
   PubMed Web of Science ®Google Scholar
• Chesney J, Puzanov I, Collichio F, et al. Randomized, open-label phase ii study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma. J Clin Oncol. 2018;36(17):1658–1667. Epub 20171005. PubMed PMID: 28981385; PubMed Central PMCID: PMC6075852
   PubMed Web of Science ®Google Scholar
• Brody JD, Ai WZ, Czerwinski DK, et al. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J Clin Oncol. 2010;28(28):4324–4332. Epub 20100809. PubMed PMID: 20697067; PubMed Central PMCID: PMC2954133
   PubMed Web of Science ®Google Scholar
• Kim YH, Gratzinger D, Harrison C, et al. In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study. Blood. 2012;119(2):355–363. Epub 20111101. PubMed PMID: 22045986; PubMed Central PMCID: PMC3257006
   PubMed Web of Science ®Google Scholar
• Algazi A, Bhatia S, Agarwala S, et al. Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients. Ann Oncol. 2020;31(4):532–540. Epub 20200201. PubMed PMID: 32147213
   PubMed Web of Science ®Google Scholar
• Altorki NK, McGraw TE, Borczuk AC, et al. Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial. Lancet Oncol. 2021;22(6):824–835. Epub 20210518. PubMed PMID: 34015311
   PubMed Web of Science ®Google Scholar
• Kwan SW, Bhargavan M, Kerlan RK, et al.Effect of advanced imaging technology on how biopsies are done and who does them.Radiology.2010;256(3):751–758; Epub 20100629. PubMed PMID: 20587643; PubMed Central PMCID: PMC2923730;
   PubMedGoogle Scholar
• O’Flynn EA, Wilson AR, Michell MJ. Image-guided breast biopsy: state-of-the-art. Clin Radiol. 2010;65(4):259–270. PubMed PMID: 20338392.
   PubMed Web of Science ®Google Scholar
• Tam AL, Kim ES, Lee JJ, et al. Feasibility of image-guided transthoracic core-needle biopsy in the BATTLE lung trial. J Thorac Oncol. 2013;8(4):436–442. PubMed PMID: 23442309; PubMed Central PMCID: PMC3879952.
   PubMedGoogle Scholar
• Moore CM, Robertson NL, Arsanious N, et al. Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review. Eur Urol. 2013;63(1):125–140. Epub 20120613. PubMed PMID: 22743165
   PubMed Web of Science ®Google Scholar
• Piccinino F, Sagnelli E, Pasquale G, et al. Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies. J Hepatol. 1986;2(2):165–173. PubMed PMID: 3958472.
   PubMed Web of Science ®Google Scholar
• Hong WX, Haebe S, Lee AS, et al. Intratumoral immunotherapy for early-stage solid tumors. Clin Cancer Res. 2020;26(13):3091–3099. Epub 2020/02/18. PubMed PMID: 32071116; PubMed Central PMCID: PMC7439755
   PubMed Web of Science ®Google Scholar
• Malek TR. The biology of interleukin-2. Annu Rev Immunol. 2008;26:453–479. PubMed PMID: 18062768.
   PubMed Web of Science ®Google Scholar
• Villarino AV, Tato CM, Stumhofer JS, et al. Helper T cell IL-2 production is limited by negative feedback and STAT-dependent cytokine signals. J Exp Med. 2007;204(1):65–71. Epub 20070116. PubMed PMID: 17227909; PubMed Central PMCID: PMC2118423
   PubMedGoogle Scholar
• Nelson BH. IL-2, regulatory T cells, and tolerance. J Immunol. 2004;172(7):125–140. PubMed PMID: 15034008.
   Google Scholar
• Rothschilds AM, Wittrup KD. What,Why, Where, and When: bringing timing to Immuno-Oncology. Trends Immunol.2019;40(1):12–21; Epub 20181210. PubMed PMID: 30545676;
   PubMedGoogle Scholar
• Mittal D, Gubin MM, Schreiber RD, et al. New insights into cancer immunoediting and its three component phases–elimination, equilibrium and escape. Curr Opin Immunol. 2014;27:16–25. Epub 20140214. PubMed PMID: 24531241; PubMed Central PMCID: PMC4388310.
   PubMed Web of Science ®Google Scholar